Why Use Mucograft?

An innovative alternative to autogenous soft tissue grafts

Mucograft® Collagen Matrix offers reduced pain¹ and morbidity by eliminating the need for a palatal donor site without compromising patients' satisfaction with the overall esthetic outcome of the procedure as compared to a connective tissue graft.²  View comparison chart.

An innovative alternative to allogenic tissue grafting

Mucograft® Collagen Matrix offers a natural alternative to allogenic soft tissue grafts.  It can be placed under a mucogingival flap or left exposed with favorable wound healing. View comparison chart.

Product Characteristics 

Mucograft® Collagen Matrix was designed to provide an off-the-shelf alternative to autologous grafts.  Clinical data demonstrates that treatment with Mucograft® can produce:

• results similar to autologous grafts when treating gingival recession defects and increasing keratinized tissue
• an increase in vestibular depth
• increased band or width of keratinized tissue around natural teeth and dental implants^1,2,3

Mucograft® consists of pure porcine collagen obtained by standardized, controlled manufacturing processes without any crosslinking or similar chemical treatment.  The collagen is extracted from veterinary certified pigs and is carefully purified to avoid antigenic reactions.

Mucograft® Collagen Matrix is indicated for covering of implants placed in immediate or delayed extraction sockets, localized gingival augmentation to increase keratinized tissue (KT) around teeth and implants, alveolar ridge reconstruction for prosthetic treatment and guided tissue regeneration procedures in recession defects for root coverage.

Product Design

Mucograft® has a uniquely designed bilayer structure optimized for soft tissue integration.

Compact Layer

The compact layer consists of compact collagen fibers that protect against bacterial infiltration in open healing situations and allow tissue adherance as a prerequisite for favorable wound healing.  This layer has a smooth texture with appropriate elastic properties to accommodate suturing.  The compact layer allows the matrix to retain its structural integrity even when wet.

Spongious Layer

The unique design of the second layer consists of a thick (2.5 - 5.0 mm), porous collagen spongious structure.  The spongious surface is placed in contact with the host tissue.  The long-fibered microstructure of Mucograft® readily absorbs fluid, facilitating organization of the blood clot, promoting formation of new blood vessels, and allowing for tissue integration within the matrix.  The spongious structure has a very high porosity of approximately 93%*, providing an optimal interconnecting pore system for fibroblast in-growth.

How does Mucograft® work?
The low antigency and excellent biocompatibility favor the use of Mucograft® in dental surgery.  Early vascularization of the porcine collagen matrix promotes rapid integration of the regenerating soft tissue.  Simultaneously, the collagen is degraded naturally with no reported evidence of device-related inflammation, yielding an optimal wound healing environment.⁴

Early Vascularization

15 days after implantation there is histologic evidence of early vascularization (rat model).  The arrow indicates the formation of blood vessels while the circles show the invasion of soft tissue cells in the 3D matrix.⁴

Histology at 30 days after implantation exhibits rapid cellular in-growth from surrounding host tissue (rat model)⁴

Clinical Evidence: Treatment of Gingival Recession Defects²

Study Design:

• 25 patients with contralateral Miller Class I or II recession defects were treated with Mucograft® (test) on one side and Connective Tissue Graft (Control) on the other.  It was required that a minimal amount of keratinized tissue was present.  Patients were evaluated and data reported post-operatively at 6 and 12 months.
• Primary Endpoint: recession depth
• Secondary Endpoints: gain of keratinized tissue, % root coverage, and patient reported values for pain, discomfort, and esthetic satisfaction at 6 and 12 months

Results: 12 Months

Clinical Evidence: Increased Keratinized Tissue¹

Study Design:

• Randomized controlled trial with 20 patients with fixed prosthetic restorations requiring enhancement of the width of keratinized tissue (Mucograft® = test, Connective Tissue Graft = control)
• Patients were required to have at least one site with < 1 mm keratinized tissue
• Primary Endpoint: six month width of keratinized tissue
• Secondary Endpoint: esthetics, periodontal health and morbidity

Results:

• Mucograft® treated sites resulted in similar gains in keratinized tissue when compared to sites treated with Connective Tissue Grafts.
• Patients experienced significantly less post-operative pain with Mucograft® by eliminating the second surgical (donor) site
• Substituting Mucograft® for a Connective Tissue Graft saved an average of 16 minutes of chairside time